The Food and Drug Administration on Thursday approved Roivant and its subsidiary Priovant's brepocitinib for the treatment of dermatomyositis, a rare autoimmune disease marked by muscle weakness and a painful skin rash.
The medicine will be marketed as Lisraya and is a once-daily pill. Roivant said dermatomyositis affects between 40,000 and 70,000 people in the U.S.
Why the approval matters
The approval adds a new treatment option in a setting where, according to the source report, high doses of steroids and other immune-suppressing drugs are the current standard of care. That gives Roivant an entry into a rare autoimmune market where an oral therapy may stand out simply by offering an alternative to established suppression-based treatment approaches.
For Roivant, the decision is also a straightforward commercial milestone: a subsidiary-developed asset has moved from development into launch with a branded product in a defined rare-disease population.
